Cytosorbents Corporation
CTSO
$0.79
$0.045.33%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -3.17M | 1.95M | -1.48M | -7.88M | -2.77M |
| Total Depreciation and Amortization | 401.00K | 440.30K | 404.70K | 425.60K | 429.00K |
| Total Amortization of Deferred Charges | 190.00K | 190.60K | 190.40K | 190.40K | 190.00K |
| Total Other Non-Cash Items | 736.00K | -5.35M | -2.19M | 6.44M | -1.62M |
| Change in Net Operating Assets | -734.00K | 1.26M | -388.00K | -1.52M | 1.30M |
| Cash from Operations | -2.58M | -1.51M | -3.47M | -2.34M | -2.46M |
| Capital Expenditure | -17.00K | -36.90K | -2.10K | -69.20K | -152.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 72.00K | -94.90K | -45.10K | -55.00K | -147.00K |
| Cash from Investing | 55.00K | -131.80K | -47.20K | -124.20K | -299.00K |
| Total Debt Issued | -- | -- | -- | 0.00 | 0.00 |
| Total Debt Repaid | -- | -- | -- | 0.00 | 0.00 |
| Issuance of Common Stock | 0.00 | -- | 6.83M | 166.90K | -- |
| Repurchase of Common Stock | -- | -1.10K | -- | -- | -41.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 0.00 | -58.00K |
| Cash from Financing | 0.00 | -1.10K | 6.83M | 166.90K | -99.00K |
| Foreign Exchange rate Adjustments | -146.00K | 259.10K | 25.90K | -105.90K | 85.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.67M | -1.38M | 3.35M | -2.41M | -2.78M |